Brooklyn ImmunoTherapeutics is a clinical-stage biopharmaceutical company focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Co. is seeking to develop IRX-2, a cytokine-based therapy, to treat patients with cancer. Co. also is exploring opportunities to advance oncology, blood disorder, and monogenic disease therapies using gene-editing and cell therapy technology through a license with Factor Bioscience Limited and through its subsidairies, Novellus, Inc. and Novellus, Ltd. We show 4 historical shares outstanding datapoints in our BTX shares outstanding history coverage, used to compute BTX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing BTX market cap history over the course of time is important for investors
interested in comparing BTX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of BTX versus a peer is one thing; comparing
BTX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like BTX can fluctuate over the course of history.
With this page we aim to empower investors researching BTX by allowing them to research the BTX market cap history. |
Free BTX Email Alerts:
Video: The Importance of Market Cap
